Compensatory activation of ErbB2 and downstream MAPK and Akt signaling in AI-resistant ER+ breast cancer cells resulted in the upregulation of miR-21 and downregulation of its target PDCD4 [49]. This evidence concerns the gene PDCD4 and breast cancer.